Pliant Therapeutics announces upcoming presentation of Phase 1 clinical trial of PLN-101095 in patients with solid tumors at the 2026 AACR Annual Meeting. Pliant Therapeutics, Inc. - GlobeNewswire - Wed Mar 18, 8:00AM CDT SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) - Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the presentation of data from the Phase 1 trial of PLN-101095 at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California from April 17-22, 2026. The abstract was selected for oral presentation as part of the Clinical Trials Mini Symposium. Oral Presentation Title: First-in-human phase I study of PLN-101095, a first-in-class dual α[v] β[8] /α[v] β[1] integrin inhibitor, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors refractory to immune checkpoint inhibitors (ICI) Presenter: Timothy A. Yap, M.D., Ph.D., University of Texas, M.D. Anderson Cancer Center Session: CTMS01: Updates in Anticancer Immunotherapies Date: Saturday, April 18, 2026 Presentation Time: 10:21 a.m. - 10:31 a.m. Pacific Time Location: Ballroom 6A - Upper Level - San Diego Convention Center Oncology Program PLN-101095 is an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins designed to overcome checkpoint resistance by blocking TGF-β activation in the tumor microenvironment. Pliant is currently conducting a Phase 1a/1b open-label, dose-escalation and indication expansion trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of PLN-101095, as monotherapy and in combination with pembrolizumab, in patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors. About Pliant Therapeutics, Inc. Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of integrin-based therapeutics. The Company's lead program is PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. Pliant's early-stage platform includes preclinical research focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules. For additional information, please visit: www.PliantRx.com. Follow us on social media X, LinkedIn and Facebook. Investor and Media Contact: Christopher Keenan Vice President, Investor Relations and Corporate Communications Pliant Therapeutics, Inc. [email protected] This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

Pliant Therapeutics has raised $120 million in a Series C round, valuing the company at $1.45 billion, as it advances PLN-101095, an oral inhibitor targeting checkpoint-resistant cancers. Phase 1 data showed four responses, including one complete response, in 10 heavily pretreated immune checkpoint inhibitor-refractory patients. Responding patients showed significant increases in plasma interferon gamma after 14 days of PLN-101095 monotherapy before adding pembrolizumab. The company has initiated a Phase 1b indication expansion trial across non-small cell lung cancer, clear cell renal cell carcinoma and high tumour mutational burden cancers. First patient enrolment is anticipated in the second quarter, with interim data expected in 2027. Pliant reported $192.4 million in cash and investments as of December 31, 2025, sufficient to fund operations into the second half of 2028.